SCHEMBL3465077

SCHEMBL3465077

Cc1cc(-n2cccn2)ccc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.45
MAPT P10636 4/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
GRM5 P41594 1/20 0.40
PDK2 Q15119 1/20 0.40
NLRP3 Q96P20 2/20 0.39
RXRA P19793 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA10 Q9GZZ6 1/20 0.39
CHRNA9 Q9UGM1 1/20 0.39
PTPN1 P18031 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11485495 0.86 KDM4E (0.49) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL255913 0.84 NOTUM (0.53) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL2191239 0.83 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL27926581 0.79 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL28687114 0.79 NOTUM (0.58) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL26921977 0.79 NOTUM (0.58) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL7632450 0.79 MAPT (0.50) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL8202120 0.79 NOTUM (0.53) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL15475872 0.79 PTPN1 (0.49) NOTUMKDM4EALDH1A1MAPK1PDK2
SCHEMBL23555483 0.77 KDM4E (0.46) NOTUMKDM4EALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148184-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2023-05-11 US disclosed
US-7737154-B2 CRF receptor antagonists and methods relating thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2010-06-15 US disclosed
US-7737154-B2 CRF receptor antagonists and methods relating thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2010-06-15 US disclosed
US-7737154-B2 CRF receptor antagonists and methods relating thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2010-06-15 US disclosed
US-7652035-B2 CRF receptor antagonists and methods relating thereto Neurocrine Bioscience, Inc. (US) 2010-01-26 US disclosed
US-7652035-B2 CRF receptor antagonists and methods relating thereto Neurocrine Bioscience, Inc. (US) 2010-01-26 US disclosed
US-7652035-B2 CRF receptor antagonists and methods relating thereto Neurocrine Bioscience, Inc. (US) 2010-01-26 US disclosed
EP-1802621-B1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SMITHKLINE BEECHAM CORK LTD (IE) 2009-05-06 EP disclosed
EP-1802621-B1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SMITHKLINE BEECHAM CORK LTD (IE) 2009-05-06 EP disclosed
US-20080064719-A1 Crf Receptor Antagonists And Methods Relating Thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2008-03-13 US disclosed
US-20080064719-A1 Crf Receptor Antagonists And Methods Relating Thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2008-03-13 US disclosed
US-20070293511-A1 Crf Receptor Antagonists and Methods SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION 2007-12-20 US disclosed
US-20070293511-A1 Crf Receptor Antagonists and Methods SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION 2007-12-20 US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 US disclosed
EP-1802621-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB Pharmco Puerto Rico Inc. (PR) 2007-07-04 EP disclosed
EP-1697374-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB Pharmco Puerto Rico Inc. (PR) 2006-09-06 EP disclosed
WO-2006044821-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB PHARMCO PUERTO RICO INC. (PR) 2006-04-27 WO disclosed
WO-2005063755-A1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO SB PHARMCO PUERTO RICO INC (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293511-A1 Crf Receptor Antagonists and Methods CRHR1, CRHR2, CRH NOTUM 4369/4885KDM4E 4388/4885ALDH1A1 1656/4885
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto CRHR1, CRHR2, CRH NOTUM 2391/4885KDM4E 4180/4885ALDH1A1 1525/4885
US-20080064719-A1 Crf Receptor Antagonists And Methods Relating Thereto CRHR1, CRHR2, SCTR NOTUM 1469/4885KDM4E 4300/4885ALDH1A1 1904/4885
US-20230148184-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 NOTUM 3680/4885KDM4E 3046/4885ALDH1A1 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.